期刊文献+

靶向治疗晚期结直肠癌新进展 被引量:1

Progress on Tartgeted Therapy for Advanced Colorectal Cancer
下载PDF
导出
摘要 结直肠癌是消化道常见的恶性肿瘤之一,其治疗方法主要以手术切除为主,辅助进行化疗和放疗,但是这些治疗方法都不能达到满意的疗效。近年来分子靶向治疗逐渐成为研究热点。有关表皮生长因子受体和血管内皮因子受体等与结直肠癌的发生、发展和转移的关系及其信号传导机制的研究也有了很大进展。因此,分子靶向药物导向治疗有望成为治疗结直肠癌的有效手段。 Colorectal cancer is one of common malignant tumors in the digestive tract, and the patient was treated with surgery and adjuvant chemotherapy and radiotherapy, but these treatments fail to achieve satisfactory results. In recent years,molecular targeted therapy has become a hot spot. Great progress has been made in the research that described the relation between epidermal growth factor, vascular endothelial growth factor receptors and the occurrence, development and transfer of colorectal cancer, its signal transmission mechanism. Therefore,the molecular targeted drug and treatment of eolorectal cancer is expected to become an effective means of treatment.
作者 唐焱 高丽霞
出处 《医学综述》 2011年第17期2620-2622,共3页 Medical Recapitulate
关键词 结直肠癌 单克隆抗体 西妥昔单抗 Colorectal cancer Monoclonal antibody Cetuximab
  • 相关文献

参考文献20

  • 1Hochster HS,Hart LL,Ramanathan RK,et al.Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer:results of the TREE Study[J].J Clin Oncol,2008,26(21):3523-3529. 被引量:1
  • 2De Primo SE,Wong LM,Khatry DB,et al.Expression profiling of blood samples from an SU 5416 phase Ⅲ metastatic colorectal cancer clinical trial:a novel strategy for biomarker identification[J].Cancer,2003,3(10):1471-2407. 被引量:1
  • 3胡伟民,邓晓芳,鲁伟群.西妥昔单抗联合伊立替康为主方案治疗晚期结直肠癌临床疗效观察[J].实用医学杂志,2007,23(16):2591-2592. 被引量:6
  • 4Arteaga CL.Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia[J].Semin Oncol,2002,29(Suppl 14):3-9. 被引量:1
  • 5Veronese ML,ODwyer PJ.Monoclonal antibodies in the treatment of colorectal cancer[J].Eur J Cancer,2004,40(9):1292-1301. 被引量:1
  • 6Mendelsohn J,Baselga J.The EGF receptor family as targets for cancer therapy[J].Oncogene,2000,19(56):6550-6565. 被引量:1
  • 7徐建明,张华.西妥昔单抗单药或与伊立替康联合治疗伊立替康耐药的转移性结直肠癌[J].循证医学,2006,6(5):274-276. 被引量:14
  • 8王若峥,陈志强,吾甫尔,王多明,刘凯.西妥昔单抗联合放化疗治疗中晚期恶性肿瘤[J].中国癌症杂志,2007,17(8):653-656. 被引量:14
  • 9Bonnet J,Giralt J,Harari P,et al.Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer:5-year survival data from a phase 3 randomised trial,and relation betweencetuximab-induced rash and survival[J].Lancet Oncol,2010,11(1):21-28. 被引量:1
  • 10Cunningham D,Humblat Y,Siena S,et al.Cetuximab monothera-PY and cetuximab plus irinotecan in irinotecan -refractory metastat.iccolorectal cancer[J].New Ensl J Med,2004,351(4):337-345. 被引量:1

二级参考文献30

共引文献37

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部